A new metabolic therapy for treating Alzheimer’s disease
Summary
This video highlights the mechanism of action of GraySpace’s patented plasmalogen precursors for treating and preventing neurodegenerative diseases including Alzheimer’s disease (AD). Plasmalogen deficiency results in impaired neurotransmission, which is believed to underlie the development and progression of AD. We believe that plasmalogen replacement will be an absolute requirement for the successful treatment of Alzheimer’s disease.